​Cardiologists question post-MI beta blockers for patients with higher LVEF as studies show no benefits

A study on beta blocker therapy has been described as “one of the most significant advances in heart attack treatment in decades”.

Cardiologists are re-evaluating their prescribing of beta blockers for patients with uncomplicated MI and left ventricular ejection fraction above 40%, as several studies question the benefits.

A randomised, open-label trial, published in The New England Journal of Medicine last week, concluded that beta blockers had no effect on mortality, secondary MI or hospitalisation for heart failure in these patients.

The study, called REBOOT, involved 8500 European participants (81% male; mean age 61), with left ventricular ejection fraction (LVEF) >40%. There was a median follow-up of 3.7 years.

Lead author Dr Borja Ibáñez called it “one of the most significant advances in heart attack treatment in decades” given that, globally, 80% of patients with uncomplicated MI were discharged on beta blockers.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .